Memorial Sloan Kettering Cancer Center

https://www.mskcc.org/healthcare-professionals

Refer a Patient to MSKCC: mskcc.org/refer

 

Insights from 2023 ASCO® Annual Meeting
H

ASCO® 2023 Insights: "PERSIST-2 Landmark OS Analysis - Spleen Volume Reduction Predicts OS in Myelofibrosis Pts on Pacritinib, But Not Best Available Therapy"

By Insights from 2023 ASCO® Annual Meeting FEATURING Helen Ajufo
By Insights from 2023 ASCO® Annual Meeting FEATURING Helen Ajufo
317 views
June 9, 2023
0 Comments
Login to view comments. Click here to Login

Featured Video

16:26
Incyte

Effects of a Treatment Option on Hematocrit Control and Spleen Volum…

Feat. C. Harrison

Featured Video

05:15
Lilly Medical Affairs

Unmet Needs for Patients With HR+, HER2- Early Breast Cancer at a Hi…

Feat. H. Rugo
MPN
04:06

ASCO® 2023 Insights: "PERSIST-2 Landmark OS Analysis - Spleen Volume…

Insights from 2023 ASCO® Annual Meeting

H. Ajufo

317 views